Cite
HARVARD Citation
Nuciforo, P. et al. (n.d.). Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.. European journal of cancer. pp. S15-S16. [Online].